N@N

OMAHA, Neb.--([ BUSINESS WIRE ])--Transgenomic, Inc. (OTCBB: TBIO) today announced the appointment of John M. McAuliffe as Vice President of Business Development, Neurology, and Matthew W. Beer as Vice President of Business Development, Oncology. Mr. McAuliffe and Mr. Beer have strong backgrounds in business development for the life sciences and will lead the Companyas expansion efforts in their respective areas of focus.

"Their respective histories of leading successful companies through significant periods of expansion and growth will prove invaluable as we pursue new strategic partnering opportunities and broaden the reach of our innovative products and services, including our breakthrough blood-based cancer gene testing technology, ICE COLD-PCR."

aJohn and Matt are key additions to the Transgenomic business development team, whose expansion represents our commitment to maximizing growth in the global commercial marketplace for genetic testing," stated Craig Tuttle, Chief Executive Officer of Transgenomic. "Their respective histories of leading successful companies through significant periods of expansion and growth will prove invaluable as we pursue new strategic partnering opportunities and broaden the reach of our innovative products and services, including our breakthrough blood-based cancer gene testing technology, ICE COLD-PCR."

John M. McAuliffe joins Transgenomic with 20 years of experience in biotech business development and in senior level sales and strategy roles. Mr. McAuliffe comes to Transgenomic from HistoRx, Inc. where he served as Vice President, Sales. Prior to HistoRx, Inc. he served as Director of Business Development at Athena Diagnostics, Inc., a leading genetic testing laboratory specializing in neurology, endocrinology, and nephrology, where he in-licensed numerous diagnostic markers, assays and technologies that led to significant sales revenues for Athena. Mr. McAuliffe holds a B.S. in Pharmacology from the University of California, Santa Barbara.

Matthew W. Beer comes to Transgenomic with 13 years of experience in life science business development, product management, and marketing. Mr. Beer was previously at Quest Diagnostics and served as Director of Oncology Marketing and Hematology/Oncology Life Cycle Leader with responsibility for strategic planning and assay development including next-generation sequencing applications. Prior to Quest Diagnostics, Mr. Beer was Vice President of Business Development at Caris Life Sciences. He has held management roles with increasing responsibility at Abbott International, Targeted Molecular Diagnostics, and Oncotech. Mr. Beer holds a B.S. in Microbiology from The University of Iowa.

About Transgenomic, Inc.

Transgenomic, Inc. ([ www.transgenomic.com ]) is a global biotechnology company advancing personalized medicine in cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The company has three complementary business divisions: Transgenomic Pharmacogenomic Services is a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; Transgenomic Clinical Laboratories specializes in molecular diagnostics for cardiology, neurology, mitochondrial disorders, and oncology; and Transgenomic Diagnostic Tools produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The company actively develops and acquires new technology and other intellectual property that strengthen its leadership in personalized medicine.

Forward-Looking Statements

Certain statements in this press release constitute aforward-looking statementsa of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.